Tag:
CSL
Latest Headlines
Latest Headlines
CSL recalling product tainted with ethylene glycol
Two companies which have fallen under the shadow of FDA inspectors in the last year initiated product recalls this week.
Baxter to erect $1B plasma plant
The company said construction will begin this year, and the facility is slated to be operational in 2018.
Vax maker CSL on road to GMP compliance
The common vaccine-making process of blending flu virus strains appears to have been a factor in the nearly 10% adverse reaction rate to CSL's Fluvax among children last year. Intermingling of the
Vax maker CSL hit with FDA warning
Flu vaccine maker CSL has been cited by the FDA for GMP failures spanning a lack of follow-through on raw material test failures to half-hearted investigations into adverse reactions suffered by
CSL sees first-half profit dip
Blood products group CSL cited foreign exchange losses, falling royalties from a drop in sales of its cervical cancer and swine-flu vaccines for a $117 million dive in first-half profit. The
CSL to boost Hizentra capacity in bid for market share
Patient convenience is a key strategy for drugmakers looking to boost sales: Think Novartis' ( $NVS ) newly approved multiple sclerosis treatment Gilenya, for example; as a pill rather than an injected
CSL predicts profit drop on lower vax sales
Australian vaccine maker CSL said full-year profit will decline as much as 6.9 percent as the end of the swine flu pandemic cuts vaccine sales, Bloomberg reports. The company predicts that net income
Plant building, expansions show growing global business
Announcements of new facilities and expansions appear to be gaining momentum. The construction work is taking place around the world. In Baltimore, Emergent BioSolutions said last week it's planning
CSL to expand, create 333 jobs
Australia's CSL is getting a boost from the Victorian government, which is backing the company's expansion of its Broadmeadows facility--a move that will create 333 new jobs by 2018, according to a
CSL execs called to FDA over plant violations
An Australian plant has fallen under the FDA's scrutiny. The agency cautioned vaccine manufacturer CSL after inspectors found problems at a plant that turns out flu vaccine, and--in a rare
